Discrete binding patterns of two heparin-reactive proteins, basic fibroblast growth factor and peptide p5R, in

Emily B Martin1, Robert Donnell2, Tina Richey1

  • 1Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA.

Insights

Peptide p5R selectively targets amyloid deposits by binding to heparan sulfate proteoglycans (HSPG) within them. Unlike basic fibroblast growth factor (bFGF), p5R avoids binding HSPG in healthy tissues, suggesting targeted amyloid detection.

Area of Science:

  • Biomedical research
  • Molecular imaging
  • Peptide therapeutics

Background:

  • Peptide p5R and basic fibroblast growth factor (bFGF) bind heparin-like molecules.
  • Heparan sulfate proteoglycans (HSPG) are involved in extracellular matrix and cell surface interactions.
  • Amyloidosis involves the accumulation of amyloid deposits, which can contain HSPG.

Purpose of the Study:

  • To compare the biodistribution of peptide p5R and bFGF in healthy and amyloidotic mice.
  • To investigate the selective binding of p5R to amyloid deposits versus bFGF.

Main Methods:

  • SPECT/CT imaging to track radiolabeled p5R and bFGF.
  • Tissue biodistribution measurements.
  • Micro-autoradiography for detailed binding analysis.

Main Results:

  • Both p5R and bFGF accumulated in the liver, spleen, and kidneys of amyloidotic mice.
  • 125I-bFGF, but not 125I-p5R, bound to HSPG in healthy tissues.
  • p5R exclusively bound to HSPG in amyloid deposits, while bFGF showed broader binding.

Conclusions:

  • Peptide p5R selectively binds to HSPG within amyloid deposits.
  • p5R demonstrates targeted binding to amyloid, unlike bFGF which binds to HSPG in both healthy and diseased tissues.
  • This selectivity suggests p5R's potential for targeted amyloid imaging or therapy.